VTAK Pemfailan SEC - Catheter Precision, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	549300I57Q6QWPFYIK27
CIK	1716621

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Catheter Precision, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

September 4, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive
September 4, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive
August 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Catheter Precision, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Catheter Precision, Inc.
August 18, 2025	EX-99.1	# # # Exhibit 99.1 Catheter Precision Receives Approval for LockeT in the United Kingdom Fort Mill, SC, August 18, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced registration and approval in the United Kingdom for its LockeT product. LockeT is a suture ret
August 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Catheter Precisio -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Co
August 15, 2025	EX-3.1	CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Catheter Precision, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secret
August 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Catheter Precision, Inc.
August 11, 2025	EX-10.6	Investment Banking Agreement dated February 11, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc. Exhibit 10.6 Strictly Confidential February 11, 2025 Catheter Precision. Inc. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 Attention: David Jenkins, Chief Executive Officer INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: We are pleased to confirm our mutual understanding regarding the retention of Ladenburg Thalmann & Co. Inc. (“Ladenburg”) by Catheter Precision, Inc., its subsidiaries, affi
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition Report Pursuant to S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of r
August 11, 2025	EX-99.1	Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025 Revenue Increased 128% Year Over Year and 48% Sequentially Exhibit 99.1 Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025 Revenue Increased 128% Year Over Year and 48% Sequentially Fort Mill, SC, AUGUST 11, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its results of oper
August 11, 2025	EX-10.1	Amendment to Investment Banking Agreement dated as of April 16, 2025 entered into by and between the Company and Ladenburg Thalmann & Co. Inc. Exhibit 10.1 Strictly Confidential April 16, 2025 Catheter Precision, Inc. 1670 Highway 160 West Suite 205 Fort Mill SC 29708 Attention: David A Jenkins Chief Executive Officer AMENDMENT TO INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: Reference is made to that certain Investment Banking Agreement ("Original Agreement") dated May 9, 2024, by and between Ladenburg Thalmann & Co. Inc. (''Ladenburg"
August 11, 2025	EX-2.1	Asset Purchase Agreement dated April 22, 2025 by and between the Company and Cardionomic (assignment for the benefit of creditors), LLC Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K BECAUSE DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE OMISSIONS ARE IDENTIFIED AS [***] ASSET PURCHASE AGREEMENT EXHIBIT LIST [included for SEC filing purposes only] EXHIBIT 1 General Assignment [omitted] EXHIBIT 1.1
August 7, 2025	424B5	Up to $1,534,372 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated May 19, 2025 (To Prospectus dated January 22, 2025) Up to $1,534,372 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with t
July 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 Catheter Precision, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 Catheter Precision, Inc.
June 26, 2025	S-8	As filed with the Securities and Exchange Commission on June 26, 2025 As filed with the Securities and Exchange Commission on June 26, 2025 Registration Statement No.
June 26, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Catheter Precision, Inc.
June 13, 2025	EX-99.1	# # # Exhibit 99.1 Catheter Precision (VTAK) Anticipates Highest LockeT Sales to Date in Q2 2025 Fort Mill, SC, June 12, 2025 – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 202
June 13, 2025	424B5	Up to $1,895,679 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT To Prospectus Supplement dated May 19, 2025 (To Prospectus dated January 22, 2025) Up to $1,895,679 Common Stock This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with t
June 13, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Catheter Precision, Inc.
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, Inc.
June 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Catheter Precision, Inc.
June 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
June 9, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
June 9, 2025	EX-4.1	Placement Agent Common Stock Purchase Warrant dated June 6, 2025 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
June 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
June 9, 2025	EX-4.1	Placement Agent Common Stock Purchase Warrant dated June 6, 2025 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
June 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Catheter Precision, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Catheter Precision, Inc.
May 30, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
May 30, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Catheter Precision, Inc.
May 30, 2025	424B3	12,859,716 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-287483 PROSPECTUS 12,859,716 Shares of Common Stock This prospectus covers the offer and resale from time to time of up to 12,859,716 shares (the “Shares”) of common stock, par value $0.0001 per share, of Catheter Precision, Inc., a Delaware corporation (the “Company”), by the Selling Stockholders identified in this prospectus, including their
May 28, 2025	CORRESP	CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 May 28, 2025 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Margaret Sawicki Re: Catheter Precision, Inc. Registration Statement on Form S-3 File No. 333-287483 Acceleration Request Requested Date: May 30, 2025 Reques
May 21, 2025	S-3	As filed with the Securities and Exchange Commission on May 21, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Catheter Precision, Inc.
May 20, 2025	424B5	Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284217 PROSPECTUS SUPPLEMENT (to Prospectus dated January 22, 2025) $1,300,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $1.3 million, from time to time solely through Ladenburg Thalmann & Co.
May 19, 2025	EX-99.1	# # # Exhibit 99.1 Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results Fort Mill, SC, May 14, 2025 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include:
May 19, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Catheter Precision, Inc.
May 19, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Catheter Precision, Inc.
May 19, 2025	EX-10.1	At the Market Offering Agreement by and between the Company and Ladenburg Thalmann & Co. Inc. Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT May 19, 2025 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Catheter Precision, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Manager”) as follows: 1. Definitions. The terms that follow, when
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition Report Pursuant to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of
May 13, 2025	EX-4.1	Form of Series L Warrant offered in May 2025. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
May 13, 2025	EX-10.2	Registration Rights Agreement dated May 12, 2025 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2025, between Catheter Precision, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase
May 13, 2025	EX-10.3	Assignment Agreement dated May 12, 2025 Exhibit 10.3 ASSIGNMENT AGREEMENT This Assignment Agreement (the "Assignment"), dated as of May 12, 2025, between Mercer Capital Global Opportunity Fund LLC (the "Assignor"), and Catheter Precision, Inc. (the "Assignee”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated May 12,
May 13, 2025	EX-10.1	Securities Purchase Agreement dated May 12, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2025, between Catheter Precision, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
May 13, 2025	EX-10.5	QHSLab Promissory Note dated July 19, 2022 Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS
May 13, 2025	EX-3.1	Certificate of Designation of Series B Preferred Stock. Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David A. Jenkins, hereby certifies that: 1. He is the Chief Executive Officer of Catheter Precision, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is aut
May 13, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Catheter Precision, Inc.
May 13, 2025	EX-10.4	QHSLab Promissory Note dated August 10, 2021 Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Catheter Precision, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Catheter Precision, Inc.
April 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file numbe
April 23, 2025	EX-2.1	Asset Purchase Agreement dated April 22, 2025* Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K BECAUSE DISCLOSURE OF SUCH INFORMATION WOULD CONSTITUTE A CLEARLY UNWARRANTED INVASION OF PERSONAL PRIVACY. THESE OMISSIONS ARE IDENTIFIED AS [***] ASSET PURCHASE AGREEMENT EXHIBIT LIST [included for SEC filing purposes only] EXHIBIT 1 General Assignment [omitted] EXHIBIT 1.1
April 23, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Catheter Precision, Inc.
April 16, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 Catheter Precision, Inc.
April 1, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Catheter Precision, Inc.
April 1, 2025	EX-99.1	# # # EXHIBIT 99.1 Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results Fort Mill, SC, March 28, 2025 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 an
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 31, 2025	EX-19.1	Insider Trading Policy dated March 21, 2025 Exhibit 19.1 CATHETER PRECISION, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (Adopted on March 21, 2025) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 2 Compliance Officers 2 Reporting violations 2 Personal
March 31, 2025	EX-3.13B	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 1/13/2025) Exhibit 3.1.3.B Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “CATHETER PRECISION, INC.”, FILED IN THIS OFFICE ON THE THIRTEENTH DAY OF JANUARY, A.D. 2025, AT 1:14 O`CLOCK P.M. AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CER
March 31, 2025	EX-10.3110	Offer Letter to Marie-Claude Jacques dated April 24, 2024 Exhibit 10.31.10 April 24, 2024 CONFIDENTIAL Marie-Claude Jacques 151B Pleasant St. Melrose, MA 02176 Dear Marie-Claude, On behalf of Catheter Precision, Inc. (the “Company” or CPI”), we are very pleased to offer you the position of Chief Commercial Officer. This position reports to the Chief Executive Officer. Your targeted start date will be May 1, 2024. This is a full-time, exempt position and
March 31, 2025	EX-21.1	Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries of Catheter Precision, Inc. Subsidiary Jurisdiction Catheter Precision, LLC Delaware PeriKard, LLC Delaware Cardionomix, Inc. Nevada
March 31, 2025	EX-10.319	Offer Letter to Philip Anderson dated January 3, 2025 Exhibit 10.31.9 January 3, 2025 CONFIDENTIAL Philip Anderson 175 Remontado Rd. PO Box 322 Boiceville, NY 12412 Dear Philip, On behalf of Catheter Precision, Inc. (the “Company” or CPI”), we are very pleased to offer you the position of Chief Financial Officer. This position reports to David Jenkins. Your targeted start date will be January 6, 2025. This is a full-time, exempt position and your sal
March 31, 2025	EX-10.318	Non-plan Stock Option Award granted January 6, 2025 to Philip Anderson Exhibit 10.31.8 Inducement Award Nonstatutory Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of January 6, 2025 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and Philip Anderson (the "Participant"). Grant Number: NP-002 Grant Date: January 6, 2025 Exercise Price per Share: $ 0.53 Number of Option Shares: 500,000 E
March 31, 2025	EX-4.2	Exhibit 4.2 Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General The following description summarizes certain terms of our capital stock and certain provisions of our amended and restated certificate of incorporation. We have adopted an amended and restated certificate of incorporation and amended and restated bylaws, and this description summarizes certain of the provisions that are included in those documents.
March 12, 2025	EX-99.1	Investor Presentation Dated March 2025 Exhibit 99.1
March 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Catheter Precision, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Catheter Precision, Inc.
February 4, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Catheter Precision, Inc.
February 3, 2025	EX-99	EXHIBIT 99 EX-99 3 ex773347.htm EXHIBIT 99 EXHIBIT 99 The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned. /s/ David Jenkins Date: February 3, 2025 DAVID JENKINS FATBOY CAPITAL, L.P. By: SEACAP MANAGEMENT LLC, General Partner By: /s/ David Jenkins Date: February 3
February 3, 2025	EX-10.2	Incentive Stock Option Agreement EX-10.2 2 ex773702.htm EXHIBIT 10.2 Exhibit 10.2 Incentive Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of January 29, 2025 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and David Jenkins (the "Participant"). Grant Number: 2023-030 Grant Date: January 29, 2025 Exercise Price per Share: $0.42 Number of Option Sha
January 17, 2025	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Catheter Precision, Inc.
January 17, 2025	CORRESP	CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 January 17, 2025 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Nicholas O’Leary Re: Catheter Precision, Inc. Registration Statement on Form S-3 File No. 333-284217 Acceleration Request Requested Date: January 22, 202
January 10, 2025	CORRESP	January 10, 2025 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 USA Main: 973-691-2000 Fax: 973-691-7573 January 10, 2025 VIA EDGAR TRANSMISSION U.
January 10, 2025	S-3	As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No.
January 10, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Catheter Precision, Inc.
January 10, 2025	EX-3.23	Proposed Form of Amendment to Certificate of Incorporation EXHIBIT 3.2.3 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc. , a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Catheter Precision, Inc. The original Certificate of Incorporation of the Corporation was filed with the Sec
January 7, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive
January 7, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2025 Catheter Precision, Inc.
January 3, 2025	EX-99	EXHIBIT A EXHIBIT A The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned. JENKINS FAMILY CHARITABLE INSTITUTE By: /s/ Casey A. Jenkins Date: January 3, 2025 Casey A. Jenkins, Trustee /s/ Casey A. Jenkins Date: January 3, 2025 CASEY A. JENKINS
November 25, 2024	DEFA14A	DEFA 14A
November 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive
November 21, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.
November 21, 2024	S-1	As filed with the Securities and Exchange Commission on November 21, 2024 As filed with the Securities and Exchange Commission on November 21, 2024 Registration No.
November 21, 2024	CORRESP	November 21, 2024 November 21, 2024 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street NE Washington, D.C. 20549 RE: Catheter Precision, Inc. Form S-1 Registration Statement To Whom It May Concern: On behalf of Catheter Precision, Inc. (the "Company"), we respectfully submit this Registration Statement on Form S-1 registering the resale of up to 10,695,962 shar
November 15, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive
November 14, 2024	EX-99.1	# # # EXHIBIT 99.1 Catheter Precision, Inc. Announces Third Quarter Update and Financial Results Fort Mill, SC, November 13, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter inclu
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report Pursuant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as
November 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Catheter Precision, Inc.
November 14, 2024	SC 13G/A	VTAK / Catheter Precision, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-vtak093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catheter Precision, Inc. (Name of Issuer) Common Stock, par value $0.0001 per shar (Title of Class of Securities) 74933X609 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch
November 13, 2024	SC 13G/A	VTAK / Catheter Precision, Inc. / INTRACOASTAL CAPITAL, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea022071814-13ga1intracathe.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catheter Precision, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 74933X609 (CUSIP Number) September 30, 2024 (Date of Event Which
November 4, 2024	EX-10.2	Investment Banking Agreement dated May 9, 2024 EXHIBIT 10.2 Strictly Confidential May 9, 2024 Catheter Precision, Inc. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 Attention: David A. Jenkins, Chief Executive Officer INVESTMENT BANKING AGREEMENT Dear Mr. Jenkins: We are pleased to confirm our mutual understanding regarding the retention of Ladenburg Thalmann & Co. Inc. (“Ladenburg”) by Catheter Precision, Inc. and its subsidiaries, affi
November 4, 2024	EX-4.2	Form of placement agent warrant offered in October 2024 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
November 4, 2024	8-K/A	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Catheter Precision, Inc.
October 30, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commissi
October 30, 2024	EX-10.1	Waiver Agreement Dated October 29, 2024 EXHIBIT 10.1 WAIVER AGREEMENT This Waiver Agreement is entered into between Catheter Precision, Inc., a Delaware corporation (the “Company”), and the Jenkins Family Charitable Institute, a family charitable entity formed in the state of Louisiana (the “Institute”), effective October 29, 2024. The Institute is the holder of 235,000 pre-funded warrants (the “Warrants”) of the Company which were acqu
October 30, 2024	SC 13D/A	VTAK / Catheter Precision, Inc. / Jenkins Family Charitable Institute - SC 13D/A Activist Investment SC 13D/A 1 cathetersc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Catheter Precision, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X 609 (CUSIP Number) B. Joseph Alley, Jr. Arnall Golden Gregory LLP 171 17th Street NW, Suite 2100 Atlanta
October 25, 2024	EX-10.1	Warrant Inducement Letter Dated October 24, 2024 EXHIBIT 10.1 CATHETER PRECISION, INC. October , 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Catheter Precision, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Series E Common Stock Purchase Warrants (the “Series E Warrants”), Series F Common Stock Purchase Warrants (the “Series F
October 25, 2024	EX-99.1	Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds EXHIBIT 99.1 Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds Fort Mill, SC, October 25, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series H and Series I warrants (
October 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Catheter Precision, Inc.
October 25, 2024	424B3	Prospectus Supplement No. 1 Dated October 25, 2024 Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-279930 and 333-281849 Prospectus Supplement dated October 25, 2024 (To the Prospectus Dated August 29, 2024) Catheter Precision, Inc. This prospectus supplement No. 1 (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus (the “Prospectus”), dated August 29,
October 25, 2024	EX-4.1	Form of Series K Warrant offered in October 2024 EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE
September 12, 2024	EX-99.1	Exhibit 1 EX-99.1 2 ea021437601ex99-1catheter.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing
September 12, 2024	SC 13G	VTAK / Catheter Precision, Inc. / INTRACOASTAL CAPITAL, LLC - SCHEDULE 13G Passive Investment SC 13G 1 ea0214376-13gintracatheter.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catheter Precision, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 74933X609 (CUSIP Number) September 3, 2024 (Date of Event Which Requires Filing of this
September 9, 2024	SC 13D	VTAK / Catheter Precision, Inc. / Jenkins Casey A. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Catheter Precision, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X 609 (CUSIP Number) B. Joseph Alley, Jr. Arnall Golden Gregory LLP 171 17th Street NW, Suite 2100 Atlanta, GA 30363 (404) 473-8500 (Name, Address
September 6, 2024	EX-99.1	1 EXHIBIT 99.1 Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering FORT MILL, SC / ACCESSWIRE / August 30, 2024 /Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the pricing of its underwritten public offering of common stock units and pre-funded units for aggregate gross proceeds of approximately $3.1
September 6, 2024	EX-1.1	Underwriting Agreement dated as of August 30, 2024, by and between Catheter Precision, Inc. and Ladenburg Thalmann & Co. Inc., as Representative of the Underwriters (incorporated by reference to Exhibit 1.1 of Company’s Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) EXHIBIT 1.1 347,277 SHARES OF COMMON STOCK SERIES H WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK SERIES I WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK SERIES J WARRANTS EXERCISABLE INTO 3,120,277 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS EXERCISABLE INTO 2,773,000 SHARES OF COMMON STOCK OF CATHETER PRECISION, INC. UNDERWRITING AGREEMENT August 30, 2024 Ladenburg Thalma
September 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 30, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commissio
September 6, 2024	EX-4.2	Form of Series I Warrant offered in September 2024 EXHIBIT 4.2 SERIES I COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES I COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
September 6, 2024	EX-99.2	Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option EXHIBIT 99.2 Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,
September 6, 2024	EX-4.5	Form of Warrant Agency Agreement dated as of September 3, 2024 entered into by and between the Registrant and Equiniti Trust Company, LLC EXHIBIT 4.5 CATHETER PRECISION, INC. and EQUINITI TRUST COMPANY, LLC (f/k/a AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC) as Warrant Agent Warrant Agency Agreement Dated as of September 3, 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of September 3, 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f
September 6, 2024	EX-4.1	Form of Series H Warrant offered in September 2024 EXHIBIT 4.1 SERIES H COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
September 6, 2024	EX-4.4	Form of Pre-Funded Warrant offered in September 2024 EXHIBIT 4.4 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Catheter Precision, Inc. Warrant Shares: 2,773,000 CUSIP: 74933X 179 ISIN: Initial Exercise Date: September 3, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi
September 6, 2024	EX-4.3	Form of Series J Warrant offered in September 2024 EXHIBIT 4.3 SERIES J COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: 3,578,900 Issue Date: September 3, 2024 THIS SERIES J COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
September 3, 2024	424B1	347,277 Common Stock Units Each Common Stock Unit Consisting of One Share of Common Stock, One Series H Warrant to Purchase One Share of Common Stock, One Series I Warrant to Purchase One Share of Common Stock, and One Series J Warrant to Purchase On Filed Pursuant to Rule 424(b)(1) Registration Nos. 333-279930 and 333-281849 PROSPECTUS 347,277 Common Stock Units Each Common Stock Unit Consisting of One Share of Common Stock, One Series H Warrant to Purchase One Share of Common Stock, One Series I Warrant to Purchase One Share of Common Stock, and One Series J Warrant to Purchase One Share of Common Stock 1,041,831 Shares of Common Stock Under
August 30, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.
August 30, 2024	S-1MEF	As filed with the Securities and Exchange Commission on August 30, 2024 As filed with the Securities and Exchange Commission on August 30, 2024 Registration No.
August 28, 2024	CORRESP	CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 August 28, 2024 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie Re: Catheter Precision, Inc. Registration Statement on Form S-1 File No. 333-279930 Acceleration Request Requested Date: August 29, 2024 R
August 28, 2024	CORRESP	Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, New York 10019 August 28, 2024 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: CATHETER PRECISION, INC. Registration Statement on Form S-1 (Registration No. 333-279930) Concurrence in Acceleration Request Ladies and Gentlemen: Ladenburg Thalm
August 27, 2024	EX-4.15	Form of Series J Warrant offered hereby EXHIBIT 4.15.3 SERIES J COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES J COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo
August 27, 2024	EX-4.15	Form of Series H Warrant offered hereby EXHIBIT 4.15.1 SERIES H COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES H COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo
August 27, 2024	EX-10.1	First Amendment to 8% Short Term Promissory Notes Payable to FatBoy Capital, L.P. EXHIBIT 10.1 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION
August 27, 2024	EX-1.1	Form of Underwriting Agreement EXHIBIT 1.1 COMMON STOCK UNITS EACH COMMON STOCK UNIT CONSISTING OF: ONE SHARE OF COMMON STOCK, ONE SERIES H WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK, ONE SERIES I WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK AND ONE SERIES J WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK PRE-FUNDED WARRANT UNITS EACH PRE-FUNDED WARRANT UNIT CONSISTING OF: ONE PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF COMMO
August 27, 2024	EX-10.335	First Amendment to Promissory Note dated May 30, 2024 EXHIBIT 10.33.5 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT
August 27, 2024	EX-10.2	First Amendment to 8% Short Term Promissory Note Payable to David A. Jenkins EXHIBIT 10.2 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION
August 27, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 Catheter Precision, Inc.
August 27, 2024	EX-4.18	Form of Warrant Agency Agreement to be entered into by and between the Registrant and Equiniti Trust Company, LLC. EXHIBIT 4.18 CATHETER PRECISION, INC. and EQUINITI TRUST COMPANY, LLC (f/k/a AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC) as Warrant Agent Warrant Agency Agreement Dated as of August , 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of August , 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a Am
August 27, 2024	EX-10.336	First Amendment to Promissory Notes dated June 25, 2024, July 1, 2024 and July 18, 2024 EXHIBIT 10.33.6 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT
August 27, 2024	EX-10.337	First Amendment to Promissory Note dated July 25, 2024 EXHIBIT 10.33.7 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICT
August 27, 2024	EX-10.3	First Amendment to 8% Short Term Promissory Note Payable to Jenkins Family Charitable Institute EXHIBIT 10.3 THE NOTE OR NOTES AMENDED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES, AND HAVE BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT THEY HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. SUCH NOTE OR NOTES ARE SUBJECT TO RESTRICTION
August 27, 2024	EX-4.15	Form of Series I Warrant offered hereby EXHIBIT 4.15.2 SERIES I COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: August [], 2024 THIS SERIES I COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo
August 27, 2024	S-1/A	As filed with the Securities and Exchange Commission on August 26, 2024 As filed with the Securities and Exchange Commission on August 26, 2024 Registration No.
August 27, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.
August 15, 2024	EX-99.1	# # # EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report. Fort Mill, SC, August 14, 2024 – Catheter Precision, Inc. (NYSE American: VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highl
August 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Catheter Precision, Inc.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report Pursuant to S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as speci
July 30, 2024	EX-10.1	Promissory Note dated July 25, 2024 EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
July 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2024 Catheter Precision, Inc.
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Catheter Precision, Inc.
July 23, 2024	EX-10.1	Promissory Note dated July 18, 2024 EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
July 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Catheter Precision, Inc.
July 12, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Catheter Precision, Inc.
July 12, 2024	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (filed 07/11/2024, effective 07/15/2024) EXHIBIT 3.1 State of Delaware Secretary of State Division of Corporations Delivered 12:32 PM 07/11/2024 FILED 12:32 FM 07/11/2024 SR 20243113811 - File Number 6788771 CATHETER PRECISION, INC. CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Catheter Precision, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), certif
July 12, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission
July 12, 2024	S-8	As filed with the Securities and Exchange Commission on July 12, 2024 As filed with the Securities and Exchange Commission on July 12, 2024 Registration Statement No.
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2024 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission F
July 3, 2024	EX-99.1	Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024 15% Quarter Over Quarter Growth – Initial Sales of LockeT Recorded EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024 15% Quarter Over Quarter Growth – Initial Sales of LockeT Recorded Fort Mill, SC, July 1, 2024 – Catheter Precision, Inc. (NYSE/American: VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including i
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Catheter Precision, Inc.
July 1, 2024	EX-10.1	Promissory Note dated July 1, 2024 EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
July 1, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Catheter Precision, Inc.
June 26, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Catheter Precision, Inc.
June 26, 2024	EX-4.18	Form of Warrant Agency Agreement to be entered into by and between the Registrant and Equiniti Trust Company, LLC. EXHIBIT 4.18 Catheter Precision, Inc. and Equiniti Trust Company, LLC (formerly known as American Stock Transfer and Trust Company), as Warrant Agent Warrant Agency Agreement Dated as of June , 2024 1 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June , 2024 (“Agreement”), between Catheter Precision, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (fo
June 26, 2024	S-1/A	As filed with the Securities and Exchange Commission on June 26, 2024 As filed with the Securities and Exchange Commission on June 26, 2024 Registration No.
June 26, 2024	EX-4.16	Form of Pre-Funded Warrant offered hereby EXHIBIT 4.16 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Catheter Precision, Inc. Warrant Shares: CUSIP: ISIN: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at
June 26, 2024	EX-1.1	Form of Underwriters' Warrant offered in September 2024 EXHIBIT 1.1 SHARES of Common Stock pre-funded warrants to purchase shares of common stock OF CATHETER PRECISION, INC. UNDERWRITING AGREEMENT June , 2024 Ladenburg Thalmann & Co. Inc. As the Representative of the Several underwriters, if any, named in Schedule I hereto 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: The undersigned, Catheter Precision, Inc., a Delaware corporat
June 26, 2024	EX-10.1	Promissory Note dated June 25, 2024 EXHIBIT 10.1 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
June 26, 2024	EX-4.17	Form of Underwriters’ Warrant Offered in September 2024 EXHIBIT 4.17 UNDERWRITER COMMON STOCK PURCHASE WARRANT CATHETER PRECISION, INC. Warrant Shares: Issue Date: , 2024 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is si
June 17, 2024	FWP	Appendix A Description of embedded animation Appendix A Description of embedded animation Slide 15 of the Presentation includes an embedded animation, without audio, that illustrates how VIVO works through a simulation of the user interface, including a 3D model of a patient, the patient’s heart, an EKG, and a user panel.
June 14, 2024	S-1/A	As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No.
June 4, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-1 (Form Type) Catheter Precision, Inc.
June 4, 2024	S-1	As filed with the Securities and Exchange Commission on June 3, 2024 As filed with the Securities and Exchange Commission on June 3, 2024 Registration No.
June 4, 2024	EX-10.31	Non-plan Stock Option Award granted May 1, 2024, to Marie-Claude Jacques EXHIBIT 10.31.7 Inducement Award Nonstatutory Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of May 1, 2024 by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and Marie-Claude Jacques (the "Participant"). Grant Number: NP-001 Grant Date: May 1, 2024 Exercise Price per Share: $ 0.5321 Number of Option Shares: 250,000 Ex
June 4, 2024	EX-10.34	Quality Agreement with Zien Medical Technologies, Inc. related to LockeT Manufacture, dated March 20, 2023 EXHIBIT 10.34 Quality Agreement 1. Administrative Elements 1.1. Scope This document defines the Quality Agreement between the parties identified below. It defines the commitment between both parties to ensure that their respective products and services satisfy the quality and regulatory requirements called out in this agreement. Both parties agree to cooperate in the success of this agreement. Thi
June 4, 2024	EX-10.28	Assignment and Agreement from Auston Locke in relation to LockeT dated July 15, 2022 EXHIBIT 10.28.2 ASSIGNMENT AND AGREEMENT WHEREAS, Auston LOCKE (hereinafter referred to singly and collectively as “ASSIGNOR”) have invented a certain invention entitled “SURGICAL VESSEL CLOSING PRESSURE DEVICE”, for which a U.S. Provisional Application was filed on February 25, 2022 as Application No. 63/314,030 and a U.S. Non Provisional Patent Application was filed on July 18, 2022 as Applicati
June 4, 2024	EX-10.28	Assignment and Agreement from David A. Jenkins in relation to LockeT dated January 24, 2023 EXHIBIT 10.28.3 ASSIGNMENT AND AGREEMENT WHEREAS, David Jenkins (hereinafter referred to singly and collectively as "ASSIGNOR") have invented a certain invention entitled "VESSEL CLOSING DEVICE", for which a U.S. Design Patent Application was filed on December 12, 2022 as Application No. 29/862,677. WHEREAS, Catheter Precision, Inc., having its principal place of business at 500 International Driv
June 3, 2024	EX-10.2	Promissory Note dated May 30, 2024 EXHIBIT 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATES. THIS NOTE HAS BEEN ISSUED IN RELIANCE UPON THE REPRESENTATION OF THE HOLDER THAT IT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TOWARDS THE RESALE OR OTHER DISTRIBUTION THEREOF. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE
June 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Catheter Precision, Inc.
June 3, 2024	EX-10.1	Invention Assignment and Royalty Agreement with Auston Locke in relation to LockeT dated May 28, 2024 EXHIBIT 10.1 Invention Assignment and Royalty Agreement This Agreement is made and entered into as of the Effective Date by and between Mr. Auston Locke, an individual residing at 4123 Costero Risco, San Clemente, CA 92673 (hereinafter “Auston”), and Catheter Precision, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business located at 1670 Highw
May 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Catheter Precision, Inc.
May 16, 2024	DEFA14A	DEFA14A
May 16, 2024	DEFA14A	1 1 2
May 16, 2024	ARS	ARS - PDF COPY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc.
May 16, 2024	ARS	ARS
May 16, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
May 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Catheter Precision, Inc.
May 7, 2024	EX-99.1	# # # EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Reports Q1 2024 Highlights and Operational Performance Report. Fort Mill, SC, May 6, 2024 – Catheter Precision, Inc. (NYSE/American: VTAK) a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q1 Financials, Operational Report for the quarter ending Mar
May 7, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
May 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report Pursuant to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as spec
April 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 Catheter Precision, Inc.
April 2, 2024	EX-99.1	# # # EXHIBIT 99.1 Catheter Precision, Inc. (NYSE American: VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023 Fort Mill, SC, April 1, 2024 – Catheter Precision, Inc. (NYSE-American: VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q4 and Annual F
April 2, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Catheter Precision, Inc.
April 1, 2024	EX-4.2	“Description of Capital Stock,” filed as Exhibit 4.2 to our Form 10-K for fiscal year ended December 31, 2023 EXHIBIT 4.2 DESCRIPTION OF CAPITAL STOCK General The following description summarizes certain terms of our capital stock and certain provisions of our amended and restated certificate of incorporation. We have adopted an amended and restated certificate of incorporation and amended and restated bylaws, and this description summarizes certain of the provisions that are included in those documents.
April 1, 2024	EX-10.313	2023 Form of Nonstatutory Stock Option Agreement for Non-Employee Directors Under 2023 Equity Incentive Plan EXHIBIT 10.31.3 Nonstatutory Stock Option Agreement For Non-Employee Directors This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company
April 1, 2024	EX-10.316	Notice of Stock Option Award granted March 13, 2021 to Margrit Thomassen under Old Catheter’s 2009 Equity Incentive Plan EXHIBIT 10.31.6 Employer Copy CATHETER PRECISION, INC. 2009 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD Unless otherwise defined herein, the terms defined in the 2009 Equity Incentive Plan shall have the same defined meanings in this Notice of Stock Option Award and the attached Stock Option Award Terms, which is incorporated herein by reference (together, the “Award Agreement”). Participan
April 1, 2024	EX-10.314	2023 Form of Nonstatutory Stock Option Agreement Under 2023 Equity Incentive Plan EXHIBIT 10.31.4 Nonstatutory Stock Option Agreement For Employees This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company hereby grant
April 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc.
April 1, 2024	EX-97	Policy Relating to the Recovery of Erroneously Awarded Compensation EXHIBIT 97 CATHETER PRECISION, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form at
April 1, 2024	EX-10.315	2023 Form of Incentive Stock Option Agreement Under 2023 Equity Incentive Plan EXHIBIT 10.31.5 Incentive Stock Option Agreement This Stock Option Agreement (this "Agreement") is made and entered into as of by and between Catheter Precision, Inc., a Delaware corporation (the "Company") and (the "Participant"). Grant Date: Exercise Price per Share: Number of Option Shares: Expiration Date: 1. Grant of Option. 1.1 Grant; Type of Option. The Company hereby grants to the Particip
February 14, 2024	SC 13G	VTAK / Catheter Precision, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-vtak123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catheter Precision, Inc. (Name of Issuer) Common Stock, par value $0.0001 per shar (Title of Class of Securities) 74933X302 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the
January 25, 2024	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Catheter Precision, Inc.
January 16, 2024	SC 13D/A	VTAK / Catheter Precision, Inc. / JENKINS DAVID A - SC 13D/A Activist Investment SC 13D/A 1 dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Catheter Precision, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X302 (CUSIP Number) B. Joseph Alley, Jr. Arnall Golden Gregory LLP 171 17th Street NW, Suite 2100 Atlanta, GA 303
January 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 Catheter Precision, Inc.
January 11, 2024	EX-99.1	CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results EXHIBIT 99.1 CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results Fort Mill, SC, January 10, 2024 – Catheter Precision, Inc. (VTAK: NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights and unaudited preliminary annual and fourth quarter re
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 Catheter Precision, Inc.
December 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 Catheter Precision, Inc.
December 22, 2023	POS AM	As filed with the Securities and Exchange Commission on December 22, 2023 As filed with the Securities and Exchange Commission on December 22, 2023 Registration No.
December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Catheter Precision, Inc.
December 22, 2023	POS AM	As filed with the Securities and Exchange Commission on December 22, 2023 As filed with the Securities and Exchange Commission on December 22, 2023 Registration No.
December 22, 2023	EX-99.1	CATHETER PRECISION, INC. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q EXHIBIT 99.1 CATHETER PRECISION, INC. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q Fort Mill, SC, December 22, 2023 – Catheter Precision, Inc. (VTAK: NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023. Highlights of the third q
December 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition Report Pursuant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as
December 18, 2023	EX-99.1	CATHETER PRECISION, INC. Reports Second Quarter Results of Operations EXHIBIT 99.1 CATHETER PRECISION, INC. Reports Second Quarter Results of Operations Fort Mill, SC, December 18, 2023 – Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (VTAK: NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023. Highlights
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Catheter Precision, Inc.
December 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report Pursuant to S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as speci
November 15, 2023	NT 10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38677 NOTIFICATION OF LATE FILING CUSIP NUMBER 74933X203 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr
August 25, 2023	EX-99.1	Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q EXHIBIT 99.1 Catheter Precision Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q Fort Mill, SC, August 25, 2023 – Catheter Precision, Inc. (the "Company") (NYSE American: VTAK) announced today that on August 22, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the
August 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Catheter Precision, Inc.
August 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 Ra Medical Systems, Inc.
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38677 NOTIFICATION OF LATE FILING CUSIP NUMBER 74933X203 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit
August 4, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 Ra Medical Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission
August 4, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (effective 08/17/23) EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF RA MEDICAL SYSTEMS, Inc. Ra Medical Systems, Inc. (hereinafter called the “Corporation,” a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: The name of the Corporation is Ra Medical Systems, Inc. SECOND: ARTICLE I of the Corporation’s Am
July 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Ra Medical Systems, Inc.
July 20, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ra Medical Systems, Inc.
July 20, 2023	S-8	As filed with the Securities and Exchange Commission on July 20, 2023 As filed with the Securities and Exchange Commission on July 20, 2023 Registration Statement No.
July 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2023 Ra Medical Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or other jurisdiction of incorporation) (Commission
July 7, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report RA MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38677 38-3661826 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 (Full mailing address
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):p July 3, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):p July 3, 2023 Ra Medical Systems, Inc.
June 26, 2023	EX-16.1	Letter re change in certifying accountant EXHIBIT 16.1 June 26, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated June 26, 2023 of Ra Medical Systems, Inc. (the “Company”) and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the Company contained in I
June 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 Ra Medical Systems, Inc.
June 26, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
June 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2023 Ra Medical Systems, Inc.
June 5, 2023	EX-99.1	Ra Medical Systems Announces First Quarter Results EXHIBIT 99.1 Ra Medical Systems Announces First Quarter Results Fort Mill, SC, June 2, 2023 – Ra Medical Systems, Inc. (RMED: NYSE/American) today announced financial and company highlights for the first quarter ended March 31, 2023. Among the quarter highlights are the following: · RMED concluded the acquisition with the private company, Catheter Precision, Inc. (“Catheter”), in January 2023. Cat
June 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report Pursuant to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Ra Medical Systems, Inc. (Exact name of registrant as spec
May 30, 2023	EX-99.1	Ra Medical Systems Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q EXHIBIT 99.1 Ra Medical Systems Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q Fort Mill, SC, May 30, 2023 – Ra Medical Systems, Inc. (the “Company”) (RMED: NYSE/American) announced today that on May 23, 2023, the Company received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE A
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Ra Medical Systems, Inc.
May 25, 2023	ARS	ARS
May 25, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
May 25, 2023	ARS	ARS
May 25, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Ra Medical Systems, Inc.
May 22, 2023	EX-99.1	Ra Medical Systems Announces Delayed 10-Q Filing EXHIBIT 99.1 Ra Medical Systems Announces Delayed 10-Q Filing Fort Mill, SC, May 22, 2023 – Ra Medical Systems, Inc. (RMED: NYSE/American) announced today that it will not file its Quarterly Report for the quarter ended March 31, 2023 within the filing deadline established by the Securities and Exchange Commission and will be a late filer with respect to such report. The delay in the filing of the
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Ra Medical Systems, Inc.
May 16, 2023	EX-99.1	Ra Medical Systems Provides First Corporate Update Since Merger Sales and Clinical Field Force Onboarded and Fully Trained First Quarter Results to be Announced on May 22, 2023 EXHIBIT 99.1 Ra Medical Systems Provides First Corporate Update Since Merger Sales and Clinical Field Force Onboarded and Fully Trained First Quarter Results to be Announced on May 22, 2023 Fort Mill, SC, May 16, 2023 – Ra Medical Systems, Inc. (RMED: NYSE/American) announced the first corporate update since the merger of the private company Catheter Precision, Inc. into the public company Ra Medi
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-Q 1 rmednt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38677 NOTIFICATION OF LATE FILING CUSIP NUMBER 74933X302 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transit
May 12, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
May 5, 2023	CORRESP	RA MEDICAL SYSTEMS, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 RA MEDICAL SYSTEMS, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 May 4, 2023 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Ra Medical Systems, Inc. Acceleration Request Registration Statement on Form S-3 Filed April 21, 2023 File No. 333-271388 Ladies and Gentlemen: In accordance wi
April 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Ra Medical Systems, Inc.
April 21, 2023	S-3	As filed with the Securities and Exchange Commission on April 21, 2023 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No.
April 21, 2023	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Ra Medical Systems, Inc.
April 19, 2023	EX-99.1	Ra Medical Announces Resignation of CEO Board Committee Seeking Replacement Ra Medical Announces Resignation of CEO Board Committee Seeking Replacement Fort Mill, SC, April 18, 2023 – Ra Medical Systems, Inc.
April 19, 2023	EX-10.1	Amendment to Change in Control and Severance Agreement, dated as of April 17, 2023, by and between Ra Medical Systems, Inc. and Jonathan Will McGuire. EXHIBIT 10.1 SECOND AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Second Amendment to Change in Control and Severance Agreement (this “Second Amendment”) is made and entered into as of the 17th day of April 2023, by and between Ra Medical Systems, Inc. (the “Company”) and Jonathan Will McGuire (the “Executive”). WHEREAS, reference is hereby made to that certain Change in Control and
April 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 Ra Medical Systems, Inc.
April 10, 2023	CORRESP	RA MEDICAL SYSTEMS, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 RA MEDICAL SYSTEMS, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 April 10, 2023 VIA EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Ra Medical Systems, Inc. Acceleration Request Registration Statement on Form S-3 Filed March 29, 2023 File No. 333-270919 Ladies and Gentlemen: In accordance
April 7, 2023	S-3/A	As filed with the Securities and Exchange Commission on April 6, 2023 As filed with the Securities and Exchange Commission on April 6, 2023 Registration No.
March 31, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT (Amendment No. 1) Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT (Amendment No.
March 31, 2023	SC 13G	RMED / Catheter Precision Inc. / R. Randall Rollins Voting Trust U/A dated August 25, 1994 - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Ra Medical Systems, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 74933X302 (CUSIP Number) W. Keith Wilkes, Jr. c/o RFA Management Company, LLC 1908 Cliff Valley Way N.E. Atlanta, GA 30329 with a copy to: Eric Orsic McDermott Will & E
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Ra Medical Systems, Inc.
March 30, 2023	EX-99.1	2 EXHIBIT 99.1 March 30, 2023 Ra Medical Systems Announces Change in Chief Financial Officer Position Previous Acting CFO Position Replaced with Permanent Appointment FORT MILL, SC / ACCESSWIRE / March 30, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving
March 29, 2023	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements give effect to the Merger. Ra Medical Systems, Inc. (“Ra Medical” or “the Company”) was preliminarily determined to be the accounting acquirer based upon the terms of the Merger and other factors including Ra Medical’s security holders retaining voting
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Ra Medical Systems, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Ra Medical Systems, Inc.
March 29, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT (Amendment No. 1) Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT (Amendment No.
March 29, 2023	S-3	As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No.
March 29, 2023	EX-99.3	CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations EX-99.3 2 rmed-ex9936.htm EX-99.3 Exhibit 99.3 CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations Comparison of the Twelve Months Ended December 31, 2021 and 2022 Revenue, Cost of Sales and Gross Profit For the twelve months ended December 31, 2021 2022 Revenue $ 148,569 $ 341,470 Cost of sales 9,633 32,555 Gross profit $ 138,936 $ 308,9
March 29, 2023	EX-99.3	CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.3 CATHETER PRECISION INC.’S Management's Discussion and Analysis of Financial Condition and Results of Operations Comparison of the Twelve Months Ended December 31, 2021 and 2022 Revenue, Cost of Sales and Gross Profit For the twelve months ended December 31, 2021 2022 Revenue $148,569 $341,470 Cost of sales 9,633 32,555 Gross profit $138,936 $308,915 Revenue Revenue is generated from t
March 29, 2023	EX-99.1	CATHETER PRECISION, INC. FINANCIAL STATEMENTS December 31, 2022 and 2021 CATHETER PRECISION, INC Exhibit 99.1 CATHETER PRECISION, INC. FINANCIAL STATEMENTS December 31, 2022 and 2021 1 CATHETER PRECISION, INC Contents Report of Independent Registered Public Accounting Firm 3 Financial Statements Balance Sheets as of December 31, 2022 and December 31, 2021 4 Statements of Operations for the years ended December 31, 2022 and 2021 6 Statements of Redeemable Convertible Preferred Stock and Stockh

VTAK / Catheter Precision, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)

Other Listings